Abstract
The α7 nicotinic acetylcholine receptor (nAChR) subtype, unlike other neuronal nicotinic receptors, exhibits a relatively high permeability to Ca++ ions. Although Ca++ entry through this receptor subtype has been implicated in various Ca++-dependent processes in the central nervous system, little is known about how this receptor modulates mammalian intracellular Ca++ dynamics. Intracellular Ca++responses evoked by activation of the human α7 nAChRs stably expressed in HEK-293 (human embryonic kidney) cells were studied. Inward current and intracellular Ca++ transients were recorded simultaneously in response to a fast drug application system. Current recordings under whole-cell voltage-clamp and fast ratiometric intracellular Ca++ imaging acquisition were synchronized to drug pulses. The mean peak [Ca++]i observed with 100 μM (−)-nicotine was 356 ± 48 nM (n = 8). The magnitude of the intracellular Ca++ elevation corresponds to a 20% fractional current carried by Ca++ ions. The EC50 of the intracellular Ca++ responses for (−)-nicotine, (±)-epibatidine, 1,1 dimethyl-4-phenyl-piperazinium and acetylcholine were 51, 3.5, 75 and 108 μM, respectively. These EC50 values strongly correlate with those recorded for the cationic inward current through α7 nAChR. α-Bungarotoxin, methyllcaconitine or extracellular Ca++chelation ablated (−)-nicotine-evoked increase in intracellular Ca++ concentration. This study provides evidence that cation influx through the human α7 nAChR is sufficient to mediate a significant, transient, rise in intracellular Ca++ concentration.
Footnotes
-
Send reprint requests to: Dr. Osvaldo Delbono, Dept. of Physiology and Pharmacology, Bowman Gray School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157.
-
↵1 Research in the laboratory of O.D. was supported by grants from the National Institutes of Health 2-P60AG10484, T-32-AG00182 and K01 AG00692 and from the Muscular Dystrophy Association (U.S.A.).
- Abbreviations:
- HEK293
- human embryonic kidney 293 cells
- nAChR
- nicotinic acetylcholine receptor
- EGTA
- ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid
- NMDA
- N-methyl-d-aspartate
- IP3
- inositol 1,4,5-triphosphate
- MLA
- methyllycaconitine
- DMPP
- 1,1 dimethyl-4-phenyl-piperazinium
- ABT-418
- (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole
- HEPES
- N-[2-hydroxyethyl]piperazine-N′-[2-ethanesulfonic acid]
- PBS
- phosphate-buffered saline
- Received May 2, 1996.
- Accepted September 3, 1996.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|